Article Information
History
- April 15, 2020.
Article Versions
- Version 1 (April 1, 2020 - 05:57).
- Version 2 (April 7, 2020 - 18:48).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Chen Shi, PhD#,1,2,
- Cong Wang, MD#,1,
- Hanxiang Wang, MD#,1,
- Chao Yang, MD5,
- Fei Cai, MD5,
- Fang Zeng, MD1,
- Fang Cheng, MD1,
- Yihui Liu, PhD1,
- Taotao Zhou, MD1,
- Bin Deng, PhD1,
- Israel Vlodavsky, PhD4,
- Jin-Ping Li, PhD3 and
- Yu Zhang, PhD*,1,2
- 1Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- 2Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, China
- 3Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
- 4Technion Integrated Cancer Center, Rappaport Faculty of Medicine, Technion, Israel
- 5Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- ↵*Corresponding author Correspondence to: Prof Yu Zhang PhD, Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong, University of Science and Technology,Wuhan, 430000, China, whxhzy{at}163.com
↵# Contributed equally
Posted April 15, 2020.
The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective clinical study
